FDA Advisers Endorse Carvykti and Abecma for Earlier Use, Despite Early Death Concerns
Washington, DC – After concerns about potential early deaths, the FDA advisers have endorsed J&J and Legend’s Carvykti, as well as BMS’ Abecma for use in earlier stages of treatment. Despite initial worries, the FDA advisory committee has ultimately given their support to the new treatment options. Carvykti, a drug developed by Johnson & Johnson and Legend Biotech, and Abecma, from Bristol Myers Squibb, have received approval for earlier use in certain circumstances. This decision …